| ADC | Antibody-drug conjugate |
| ADCC | Antibody-dependent cell-mediated cytotoxicity |
| AI | Aromatase inhibitor |
| Akt | Protein kinase B |
| AMPK | Adenosine monophosphate-activated protein kinase |
| APC | Antigen-presenting cell |
| ATM | Ataxia telangiectasia-mutated kinase |
| ATP | Adenosine triphosphate |
| BC | Breast cancer |
| BRCA | Breast cancer-associated protein |
| CDK | Cyclin-dependent kinase |
| CK | Cytokeratins |
| CNS | Central nervous system |
| DNA | Deoxyribonucleic acid |
| dsDNA | Double-stranded deoxyribonucleic acid |
| EGFR/ERB | Epidermal growth factor receptor |
| ER | Estrogen receptor |
| FDA | Food and drug administration |
| gBRCA | Germline breast cancer associated protein gene |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| HER1 | Human epidermal growth factor receptor 1 |
| HER2 | Human epidermal growth factor receptor 2 |
| HER3 | Human epidermal growth factor receptor 3 |
| HER4 | Human epidermal growth factor receptor 4 |
| HLA-A2 | Human leukocyte antigen-A2 |
| HR | Hormone receptor |
| HRR | Homologous recombination repair |
| LKB1 | Liver kinase B1 |
| LumA | Luminal-A |
| LumB | Luminal-B |
| mTOR | Mammalian target of rapamycin |
| NAD+ | Nicotinamide adenine dinucleotide |
| NHEJ | Non-homologous end joining |
| PAM | PI3K/Akt/mTOR pathway |
| PARP | Poly-ADP-ribose polymerase |
| PARPi | Poly-ADP-ribose polymerase inhibitor |
| PARylation | Poly-ADP-ribosylation |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene |
| PIP2 | Phosphatidylinositol-4,5-biphosphate |
| PIP3 | Phosphatidylinositol-3,4,5-triphosphate |
| PI3K | Phosphoinositide 3-kinase |
| PR | Progesterone receptor |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed cell death ligand 1 |
| PTEN | Phosphatase and tensin homolog |
| Rb | Retinoblastoma protein |
| RTK | Receptor tyrosine kinase |
| SERD | Selective estrogen receptor degrader |
| SERM | Selective estrogen receptor modulator |
| TAA | Tumor-associated antigen |
| T-DM1 | Trastuzumab emtansine |
| T-DXd | Trastuzumab deruxtecan |
| TGF-β | Transforming growth factor beta |
| TKI | Tyrosine kinase inhibitor |
| TNBC | Triple-negative breast cancer |
| Trop-2 | Trophoblast cell-surface antigen 2 |